Janus kinase inhibitors in severe alopecia areata: balancing patient expectations with clinician safety considerations
An ethical dilemma of a patient with severe alopecia areata insisting on treatment with a novel oral Janus kinase inhibitor, despite the dermatologist expressing reservations about the patient’s cardiovascular risk factors.
Authors
- Neil P Patel (ORCID: https://orcid.org/0000-0003-2613-6056)
- E Jackson (ORCID: https://orcid.org/0009-0004-5535-5981)
Institutions
- Imperial College Healthcare NHS Trust (GB)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1093/ced/llaf541
- Primary Topic
- Hair Growth and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00